Citations

Showing 10 of 108119 citations.

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Wallentin, Lars , Andersson, Ulrika , Alexander, John H. , Caterina, Raffaele De , Granger, Christopher B. , Halvorsen, Sigrun , Hanna, Michael , Huber, Kurt , Siegbahn, Agneta , Hanna, Michael G. , Huber, Kurt , Granger, Christopher B , Christersson, Christina , Alings, Marco , Gersh, Bernard J. , Hylek, Elaine M. , Lópes, Renato D. , Oh, Byung‐Hee

Mayo Clinic

Heart | February 16, 2019 | Volume: 105 | Issue: 3 | Pages: 235-242

10.1136/heartjnl-2018-313351 | PMID 30209126 Get It

Objectives Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF). Methods The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial included 4850 patients with AF randomised to treatment with apixaban or warfarin. Sixty per cent of patients used vitamin K antagonist (VKA) within 7 days before randomisation. Prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand (sCD40L) and von Willebrand factor (vWF) antigen were analysed at randomisation and after 2 months of study treatment. Results In patients not on VKA treatment at randomisation, F1+2 and D-dimer levels were decreased by 25% and 23%, respectively, with apixaban, and by 59% and 38%, respectively, with warfarin (p<0.0001 for treatment differences for both). In patients on VKA at randomisation, F1+2 and D-dimer levels increased by 41% and 10%, respectively, with apixaban and decreased by 37% and 11%, respectively, with warfarin (p<0.0001 for treatment differences for both). sCD40L levels were slightly increased at 2 months, regardless of VKA or randomised treatment. Apixaban and warfarin also both reduced vWF antigen regardless of VKA treatment. The efficacy (stroke) and safety (bleeding) of apixaban compared with warfarin was similar irrespectively of biomarker levels at 2 months. Conclusions Treatment with apixaban compared with warfarin for stroke prevention in patients with AF was associated with less reduction in thrombin generation and fibrin turnover. This effect of apixaban could contribute to the clinical results where apixaban was superior to warfarin both in stroke prevention and in reducing bleeding risk. Trial registration number NCT00412984.
Acute Non-Traumatic Spontaneous Auricular Hematoma
Mohseni, Michael , Szymanski, Theodore, Mohseni, Michael M

Mayo Clinic

American Journal of Case Reports | February 16, 2019 | Volume: 20 | Issue: No issue available | Pages: 204-206

10.12659/ajcr.913464 | PMID 30770527 Get It

Ex Vivo Hepatocyte Reprograming Promotes Homology‐Directed DNA Repair to Correct Metabolic Disease in Mice After Transplantation
Guthman, Rebekah M., Nicolas, Clara T., Allen, Kari L. , Liu, Yuanhang , Chilton, Jennifer A., Tritz, Zachariah P. , Nyberg, Scott L. , Kaiser, Robert A. , Lillegard, Joseph B. , VanLith, Caitlin J. , Hickey, Raymond D, Hickey, Raymond

Mayo Clinic

Hepatology Communications | February 16, 2019 | Volume: 3 | Issue: 4 | Pages: 558-573

10.1002/hep4.1315 | PMID 30976745 Get It

Ex vivo CRISPR/Cas9‐mediated gene editing in hepatocytes using homology‐directed repair (HDR) is a potential alternative curative therapy to organ transplantation for metabolic liver disease. However, a major limitation of this approach in quiescent adult primary hepatocytes is that nonhomologous end‐joining is the predominant DNA repair pathway for double‐strand breaks (DSBs). This study explored the hypothesis that ex vivo hepatocyte culture could reprogram hepatocytes to favor HDR after CRISPR/Cas9‐mediated DNA DSBs. Quantitative PCR (qPCR), RNA sequencing, and flow cytometry demonstrated that within 24 hours, primary mouse hepatocytes in ex vivo monolayer culture decreased metabolic functions and increased expression of genes related to mitosis progression and HDR. Despite the down‐regulation of hepatocyte function genes, hepatocytes cultured for up to 72 hours could robustly engraft in vivo. To assess functionality long‐term, primary hepatocytes from a mouse model of hereditary tyrosinemia type 1 bearing a single‐point mutation were transduced ex vivo with two adeno‐associated viral vectors to deliver the Cas9 nuclease, target guide RNAs, and a 1.2‐kb homology template. Adeno‐associated viral Cas9 induced robust cutting at the target locus, and, after delivery of the repair template, precise correction of the point mutation occurred by HDR. Edited hepatocytes were transplanted into recipient fumarylacetoacetate hydrolase knockout mice, resulting in engraftment, robust proliferation, and prevention of liver failure. Weight gain and biochemical assessment revealed normalization of metabolic function. Conclusion: The results of this study demonstrate the potential therapeutic effect of ex vivo hepatocyte‐directed gene editing after reprogramming to cure metabolic disease in a preclinical model of hereditary tyrosinemia type 1.
The early proximal αβ TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network
Neier, Steven C. , Ferrer, Alejandro , Wilton, Katelynn M. , Smith, Stephen , Kelcher, April M. Huseby , Pavelko, Kevin D. , Canfield, Jenna M. , Davis, Tessa R. , Stiles, Robert J. , Chen, Zhenjun , McCluskey, James , Rossjohn, Jamie , Hebrink, Deanne, Carmona, Eva M. , Kappes, Dietmar J. , Wettstein, Peter J., Johnson, Aaron J. , Pease, Larry R. , Neuhauser, Claudia , Gil, Diana , Schrum, Adam G. , Smith, Stephen E P , Kelcher, April M H , Rossjohn, Jamie , Hebrink, Deanne M, Johnson, Aaron J. , Daniels, Mark A , Neuhauser, Claudia , Gil, Diana , Schrum, Adam G , Carmona, Eva M , Pavelko, Kevin D , Canfield, Jenna M , Burrows, Scott R. , Limper, Andrew H. , Daniëls, Mark A. , Ferrer, Alejandro

Mayo Clinic

Science Immunology | February 16, 2019 | Volume: 4 | Issue: 32 | Pages: No page available

10.1126/sciimmunol.aal2201 | PMID 30770409 Get It

Quantitative activity through the TCR-proximal protein network specifies thymic positive versus negative selection.
Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685
Lowe, Val J. , Duan, Fenghai , Subramaniam, Rathan M. , Sicks, JoRean D., Romanoff, Justin , Bartel, Twyla B. , Yu, Jian Q. , Cognetti, David M. , Stack, Brendan C. , Nussenbaum, Brian A. , Richmon, Jeremy D. , Arnold, Charles D.

Mayo Clinic

Journal of Clinical Oncology | February 15, 2019 | Volume: 37 | Issue: 20 | Pages: 1704-1712

10.1200/jco.18.01182 | PMID 30768363 Get It

PURPOSE The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions. PET/CT was compared with findings at neck dissection. RESULTS PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participants. For visual assessment, the NPV specific to the clinical-N0 sides was 0.868 (95% CI, 0.803 to 0.925). For dichotomized maximum standardized uptake value, the NPVs specific to the nodal basins were 0.940 (95% CI, 0.928 to 0.952) and 0.937 (95% CI, 0.925 to 0.949) at prespecified cutoffs of 2.5 and 3.5, respectively. The optimal cutoff maximum standardized uptake value was determined to be 1.8, with an NPV of 0.942 (95% CI, 0.930 to 0.953). The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22%) compared with the PET/CT-blinded surgical plan. In 34 participants (14%), this led to planned dissection of additional nodal levels. In 12 participants (5%), this led to fewer planned dissected nodal levels. Negative PET/CT scans in N0 necks was true negative in 87% and false negative in 13%. CONCLUSION [18F]fluorodeoxyglucose-PET/CT has high NPV for the N0 neck in T2 to T4 HNSCC. The surgical treatment plans on the basis of PET/CT findings may be changed in approximately 22% of this group. These findings suggest that [18F]fluorodeoxyglucose-PET/CT may assist the clinician in deciding on the best therapy for the clinically N0 neck in HNSCC. Well-designed clinical trials should be performed to test the outcome of omitting neck dissection by using PET/CT.
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies
Croft, Cara L. , Ryu, Daniel, Ceballos‐Diaz, Carolina, Strang, Kevin H., Woody, Brittany M. , Lin, Wen-Lang, DeTure, Michael , Rodríguez-Lebrón, Edgardo, Chakrabarty, Paramita , Levites, Yona , Giasson, Benoit I. , Golde, Todd E. , Woody, Brittany M , Chakrabarty, Paramita , Golde, Todd E , Cruz, Pedro E. , Dickson, Dennis W.

Mayo Clinic

Journal of Experimental Medicine | February 15, 2019 | Volume: 216 | Issue: 3 | Pages: 539-555

10.1084/jem.20182184 | PMID 30770411 Get It

It has been challenging to produce ex vivo models of the inclusion pathologies that are hallmark pathologies of many neurodegenerative diseases. Using three-dimensional mouse brain slice cultures (BSCs), we have developed a paradigm that rapidly and robustly recapitulates mature neurofibrillary inclusion and Lewy body formation found in Alzheimer’s and Parkinson’s disease, respectively. This was achieved by transducing the BSCs with recombinant adeno-associated viruses (rAAVs) that express α-synuclein or variants of tau. Notably, the tauopathy BSC model enables screening of small molecule therapeutics and tracking of neurodegeneration. More generally, the rAAV BSC “toolkit” enables efficient transduction and transgene expression from neurons, microglia, astrocytes, and oligodendrocytes, alone or in combination, with transgene expression lasting for many months. These rAAV-based BSC models provide a cost-effective and facile alternative to in vivo studies, and in the future can become a widely adopted methodology to explore physiological and pathological mechanisms related to brain function and dysfunction.
Canstem111P Trial: A Phase Iii Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine
Sonbol, Mohamad Bassam , Ahn, Daniel H. , Goldstein, David , Tabernero, Josep , Macarulla, Teresa , Reni, Michele , O’Neil, Bert H. , Bekaii‐Saab, Tanios , Sonbol, Mohamad B , Tabernero, Josep , Bekaii-Saab, Tanios S , Okusaka, Takuji , Li, Chung‐Pin , Cutsem, Eric Van , Macarulla, Teresa

Mayo Clinic

Future Oncology | February 15, 2019 | Volume: 15 | Issue: 12 | Pages: 1295-1302

10.2217/fon-2018-0903 | PMID 30768369 Get It

Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing Congenital Disorders of Glycosylation by Use of Flow Injection–Electrospray Ionization–Quadrupole Time-of-Flight Mass Spectrometry
Li, Xueli , Edmondson, Andrew C. , Meyers, Gail Ditewig, Izumi, Kosuke , Ackermann, Amanda M. , Bennett, Michael J. , He, Miao , Edmondson, Andrew C , Chen, Jie , Morava, Éva , Ficicioglu, Can H.

Mayo Clinic

Clinical Chemistry | February 15, 2019 | Volume: 65 | Issue: 5 | Pages: 653-663

10.1373/clinchem.2018.296780 | PMID 30770376 Get It

Abstract BACKGROUND Congenital disorders of glycosylation (CDG) represent 1 of the largest groups of metabolic disorders with &gt;130 subtypes identified to date. The majority of CDG subtypes are disorders of N-linked glycosylation, in which carbohydrate residues, namely, N-glycans, are posttranslationally linked to asparagine molecules in peptides. To improve the diagnostic capability for CDG, we developed and validated a plasma N-glycan assay using flow injection–electrospray ionization–quadrupole time-of-flight mass spectrometry. METHODS After PNGase F digestion of plasma glycoproteins, N-glycans were linked to a quinolone using a transient amine group at the reducing end, isolated by a hydrophilic interaction chromatography column, and then identified by accurate mass and quantified using a stable isotope-labeled glycopeptide as the internal standard. RESULTS This assay differed from other N-glycan profiling methods because it was free of any contamination from circulating free glycans and was semiquantitative. The low end of the detection range tested was at 63 nmol/L for disialo-biantennary N-glycan. The majority of N-glycans in normal plasma had &lt;1% abundance. Abnormal N-glycan profiles from 19 patients with known diagnoses of 11 different CDG subtypes were generated, some of which had previously been reported to have normal N-linked protein glycosylation by carbohydrate-deficient transferrin analysis. CONCLUSIONS The clinical specificity and sensitivity of N-glycan analysis was much improved with this method. Additional CDGs can be diagnosed that would be missed by carbohydrate-deficient transferrin analysis. The assay provides novel biomarkers with diagnostic and potentially therapeutic significance.
Human Fibrinogen for Maintenance and Differentiation of Induced Pluripotent Stem Cells in Two Dimensions and Three Dimensions
Gandhi, Jarel K. , Knudsen, Travis, Hill, Matthew, Bachman, Lori A. , Pfannkoch‐Andrews, Cynthia, Schmidt, Karina N., Metko, Muriel M., Ackerman, Michael J. , Resch, Zachary T., Pulido, José S. , Marmorstein, Alan D. , Bachman, Lori, Pfannkoch-Andrews, Cynthia, Resch, Zachary, Roy, Bhaskar , Marmorstein, Alan D

Mayo Clinic

Stem Cells Translational Medicine | February 15, 2019 | Volume: 8 | Issue: 6 | Pages: 512-521

10.1002/sctm.18-0189 | PMID 30768863 Get It

Abstract Human fibrin hydrogels are a popular choice for use as a biomaterial within tissue engineered constructs because they are biocompatible, nonxenogenic, autologous use compatible, and biodegradable. We have recently demonstrated the ability to culture induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium on fibrin hydrogels. However, iPSCs themselves have relatively few substrate options (e.g., laminin) for expansion in adherent cell culture for use in cell therapy. To address this, we investigated the potential of culturing iPSCs on fibrin hydrogels for three-dimensional applications and further examined the use of fibrinogen, the soluble precursor protein, as a coating substrate for traditional adherent cell culture. iPSCs successfully adhered to and proliferated on fibrin hydrogels. The two-dimensional culture with fibrinogen allows for immediate adaption of culture models to a nonxenogeneic model. Similarly, multiple commercially available iPSC lines adhered to and proliferated on fibrinogen coated surfaces. iPSCs cultured on fibrinogen expressed similar levels of the pluripotent stem cell markers SSea4 (98.7% ± 1.8%), Oct3/4 (97.3% ± 3.8%), TRA1-60 (92.2% ± 5.3%), and NANOG (96.0% ± 3.9%) compared with iPSCs on Geltrex. Using a trilineage differentiation assay, we found no difference in the ability of iPSCs grown on fibrinogen or Geltrex to differentiate to endoderm, mesoderm, or ectoderm. Finally, we demonstrated the ability to differentiate iPSCs to endothelial cells using only fibrinogen coated plates. On the basis of these data, we conclude that human fibrinogen provides a readily available and inexpensive alternative to laminin-based products for the growth, expansion, and differentiation of iPSCs for use in research and clinical cell therapy applications. Stem Cells Translational Medicine 2019;8:512–521
Substratification of patients with newly diagnosed standard‐risk multiple myeloma
Binder, Moritz , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson , Kumar, Shaji K , Binder, Moritz , Russell, Stephen J , Rajkumar, S. Vincent , Ketterling, Rhett P. , Dispenzieri, Angela , Gertz, Morie A. , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

British Journal of Haematology | February 15, 2019 | Volume: 185 | Issue: 2 | Pages: 254-260

10.1111/bjh.15800 | PMID 30768679 Get It

SummaryDespite the absence of high‐risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high‐risk phenotype among standard‐risk patients. Fifty‐six percent of all patients presented with standard‐risk disease. Among them, advanced age, extremes of body mass index, non‐hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard‐risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high‐risk patients. Two or more adverse factors were present in 17% of standard‐risk patients and were associated with OS comparable to high‐risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard‐risk patients was improved using score groups compared to ISS stages. Patients with standard‐risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high‐risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.